Cleared Traditional

K823138 - CELL SCRAPER

K823138 is the FDA 510(k) clearance for CELL SCRAPER by Corning Costar Corp.. It is a Class 1 Hematology device (product code KJA) cleared through the Traditional 510(k) pathway after a 35-day FDA review.

K823138 · Corning Costar Corp. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1982
Decision
35d
Days
Class 1
Risk

K823138 is an FDA 510(k) clearance for the CELL SCRAPER. Classified as Flask, Tissue Culture (product code KJA), Class I - General Controls.

Submitted by Corning Costar Corp. (Mchenry, US). The FDA issued a Cleared decision on November 29, 1982 after a review of 35 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.2240 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Corning Costar Corp. devices

Submission Details

510(k) Number K823138 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 25, 1982
Decision Date November 29, 1982
Days to Decision 35 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
78d faster than avg
Panel avg: 113d · This submission: 35d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KJA Flask, Tissue Culture
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.2240
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.